المؤلفون: Galina Viktorovna Lukina, Ya A Sigidin, Г. В. Лукина, Я. А. Сигидин

المصدر: Modern Rheumatology Journal; Том 6, № 2 (2012); 44-49 ; Современная ревматология; Том 6, № 2 (2012); 44-49 ; 2310-158X ; 1996-7012 ; 10.14412/1996-7012-2012-2

مصطلحات موضوعية: цертолизумаб пегол, certolizumab pegol

وصف الملف: application/pdf

Relation: https://mrj.ima-press.net/mrj/article/view/412/390; Beevor C.P., Hull R., Thomas A. et al. Anti TNFa therapy reduce emergency health services usage. Ann Rheum Dis 2006; 65(Suppl. II): 176. Никишина И.П., Родионовская С.Р. Терапия рефрактерных вариантов ювенильного артрита. Cons med 2006 (прил. Педиатрия); 2: 85-9. Finzel S., Rech J., Schmidt S. et al. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of erosion. Ann Rheum Dis 2011; 70: 1587-93. Fossati G., Nesbitt A. Certolizumab pegol has a different profile from the other anti-TNFs, including golimumab, in a variety of in vitro assays. Ann Rheum Dis 2010; 69(Suppl. 3): 324. Palframan R., Ayrey M., Moore A. et al. Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritis. J Immunol Meth 2009; 348: 36-41. Schrelber S., Khalig-Kaaremi M., Lawrance I. et al. Certolizumab pegol, a pegylated Fab’ fragment of a humanised anti-TNF monoclonal antibody, is safe and effective in the maintenance of response and remission following induction in active Crohn’s disease: a phase III study. Ann Rheum Dis 2006; 65(Suppl. II): 500. Насонов Е.Л., Амирджанова В.Н. Новые аспекты фармакотерапии ревматоидного артрита: фокус на цертолизумаб пе-гол. Науч.-практ. ревматол. 2011; 1: 40-9. Fleischmann R., Vencovsky J., van Vollenhoven R. et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009; 68: 805-11. Keystone E.C., Curtis J.R., Fleischmann R.M. et al. Rapid improvement in signs and symptoms of rheumatoid arthritis following certolizumab pegol treatment predicts better longterm outcomes: Post-hoc analysis of randomized controlled trial. J Rheumatol. First release March 1, 2011; doi:10.3899/jrheum.100935. Keystone E., van der Heide D., Mason D. et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Arthr Rheum 2008; 58: 3319-29. Smolen J., Landewe R.B., Mease P. et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009; 68: 797-804. Weinblatt M., Fleischmann R., van Vollenhoven R. et al. Certolizumab pegol as monotherapy or with concomitant DMARDs in patients with active rheumatoid arthritis (RA) with or without prior TNF inhibitor use: analysis of the realistic 12-week phase III randomised controlled study. Ann Rheum Dis 2011; 70(Suppl. 3): 414. Smolen J., Emery P., Ferraccioli G. et al. Efficacy and safety of certolizumab pegol after incomplete response to DMARDs in RA patients with low moderate disease activity: Results from CERTAIN, a phase IIIb study. Ann Rheum Dis 2011; 70(Suppl. 3): 259. Gallego-Galisteo M., Villa-Rubio A., Alegre-del Rey E. et al. Indirect comparison of biological treatment in refractory rheumatoid arthritis. J Clin Pharm Ther doi:10.1111/j.1365—2710.2011.01292.x Mease P.G., Keystone E., Mason D. et al. Safety of сertolizumab pegol with methotrexate in patients with active rheumatoid arthritis. Ann Rheum Dis 2008; 67 (Suppl. II): 324-5. Singh J.A., Wells G., Christensen R. et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database of Systematic Reviews, 2011; Is. 2. Wolf D., Mahadevan U. Certolizumab Pegol use in pregnancy: low levels detected in cord blood. Arthr Rheum 2010; 62 (Suppl. 10): 299.; https://mrj.ima-press.net/mrj/article/view/412

الاتاحة: https://mrj.ima-press.net/mrj/article/view/412
https://doi.org/10.14412/1996-7012-2012-727

المؤلفون: Лукина, Галина, Сигидин, Я.

مصطلحات موضوعية: РЕВМАТОИДНЫЙ АРТРИТ, ЦЕРТОЛИЗУМАБ ПЕГОЛ

وصف الملف: text/html

الاتاحة: http://cyberleninka.ru/article/n/tsertolizumab-pegol-v-terapii-revmatoidnogo-artrita
http://cyberleninka.ru/article_covers/14046442.png

المصدر: Современная ревматология.

مصطلحات موضوعية: РЕВМАТОИДНЫЙ АРТРИТ, ЦЕРТОЛИЗУМАБ ПЕГОЛ

وصف الملف: text/html

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______2806::3f46ec532c23e841bc33e37448d4b91c
http://cyberleninka.ru/article_covers/14046442.png